BioMarin Negotiates For Aldurazyme With Sanofi-Aventis
This article was originally published in The Pink Sheet Daily
Executive Summary
The mash-up between Sanofi and Genzyme will have a large effect on one of the biotech's other partners.
You may also be interested in...
Au Revoir Genzyme; Sanofi Stakes Its Claim With $20.1 Billion Upfront And CVRs
Sanofi-Aventis finally struck a deal to acquire Genzyme for $20.1 billion plus potential future payments, but successfully integrating the company remains the challenge.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.